Join the 'Aplastic Anemia' group to help and get support from people like you.
Aplastic Anemia News
Posted 18 Jun 2015 by Drugs.com
-- Anemia occurs when there are insufficient red blood cells, or they don't function properly. The American Society of Hematology says warning signs include: Feeling weak or dizzy. Having colder hands and feet. Having pale skin or a yellow tint. Feeling short of breath. Having an irregular or fast heartbeat. Hearing a whooshing sound or pounding in the ears. Having frequent chest pain or headache. Read more
Related support groups: Anemia, Iron Deficiency Anemia, Anemia - Sickle Cell, Folic Acid Deficiency, Aplastic Anemia, Pernicious Anemia, B12 Nutritional Deficiency, Anemia Associated with Iron Deficiency, Autoimmune Hemolytic Anemia, Hemolytic Anemia, Anemia, Megaloblastic, Anemia Associated with Chronic Disease, Anemia - Posthemorrhagic, Erythroblastopenia, Schilling Test, Anemia Associated with Vitamin B12 Deficiency, G-6-PD Deficiency, Anemia Associated with Prematurity, Folic Acid/Cyanocobalamin Deficiency, Anemia of Unspecified Nutritional Deficiency
Posted 27 Aug 2014 by Drugs.com
London, UK – 26 August 2014 – GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the once-daily use of Promacta (eltrombopag) in patients with severe aplastic anemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).1 SAA is a blood disorder where the bone marrow fails to make enough red blood cells, white blood cells, and platelets.2 Eltrombopag, an oral thrombopoietin (TPO) receptor agonist, works by helping to induce proliferation and differentiation of bone marrow stem cells to increase production of blood cells.1 “FDA approval of Promacta addresses a significant treatment need for this very rare but serious blood disorder in those who have failed current treatment options,” said Dr. Paolo Paoletti, President of Oncology, GSK. “Through colla ... Read more